A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes
NCT ID: NCT05794581
Last Updated: 2024-12-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
32 participants
INTERVENTIONAL
2023-03-21
2024-04-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CT-868
SC injection of CT-868 Intervention
CT-868
CT-868
Placebo
SC injection of placebo matching CT-868 dose
Placebo
Placebo as SC Injection
Victoza
SC injection of active comparator
Victoza
Victoza as active comparator as SC Injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CT-868
CT-868
Placebo
Placebo as SC Injection
Victoza
Victoza as active comparator as SC Injection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ages 18-65 years
* Type 1 DM for at least 3 years
* Using an insulin pump or multiple daily injections (MDI) for at least 3 months
* BMI 25.0 - 35.0
Exclusion Criteria
* Uncontrolled diabetes
* History of surgical treatment for weight loss
* History of malignancy
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Carmot Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Carmot Clinical Research Unit 101
Chula Vista, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Carmot Therapeutics, Inc.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CT-868-005
Identifier Type: -
Identifier Source: org_study_id